Association between early anti-cytomegalovirus therapy and the incidence of chronic graft-versus-host disease
International Journal of Hematology · 2025
DOI: 10.1007/s12185-024-03871-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Hematology, 2025. Verfasst von Kotaro Miyao und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, Aichi, 446-8602, Japan. koutarou380@kosei.anjo.aichi.…. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Ganciclovir, Cytomegalovirus Infections. Die Arbeit nennt 44 Literaturangaben.
Abstract (Originalsprache)
Ganciclovir and foscarnet are two representative anti-cytomegalovirus (CMV) agents. A previous regional study revealed a lower risk of chronic graft-versus-host disease (GVHD) in patients who received pre-emptive foscarnet. We conducted a retrospective nationwide study to confirm the results. A total of 8890 patients aged 16 or older with hematological malignancies who received foscarnet (n = 1555) or ganciclovir (n = 7335) during their first hematopoietic stem cell transplantation (HSCT) were included. The risks of chronic GVHD (hazard ratio [HR], 1.26; 95% confidence interval [CI], 1.13-1.40; P < 0.001) and extensive chronic GVHD (HR, 1.16; 95% CI, 1.01-1.33; P = 0.033) were higher with ganciclovir. Among male patients with a female donor, the incidence of extensive chronic GVHD 3 years after HSCT was clearly lower with foscarnet (13%; 95% CI, 9-16%) than with ganciclovir (27%; 95% CI, 25-29%; P < 0.001). In male patients who received HSCT from female donors, foscarnet recipients showed significantly lower incidence of extensive chronic GVHD than ganciclovir recipients, regardless of donor source or previous acute GVHD. While caution is necessary, these results indicate that foscarnet affects alloimmunization and might reduce the incidence of chronic GVHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, Aichi, 446-8602, Japan. koutarou380@kosei.anjo.aichi.jp.
- Department of Hematology, Shiga University of Medical Science, Otsu, Japan.
- Department of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
- Department of Hematology, Toranomon Hospital, Tokyo, Japan.
- Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
- Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Zitieren
APA
Miyao, K., Murata, M., Nishida, T., Ozawa, Y., Uchida, N., Fukuda, T., Doki, N., Eto, T., Kawakita, T., Mori, Y., Takada, S., Ohigashi, H., Tanaka, M., Kanda, Y., Matsuoka, K. I., Ishimaru, F., Atsuta, Y., Kanda, J., Terakura, S., & GVHD Working Group of the Japanese Society for Transplantation and Cellular Therapy (2025). Association between early anti-cytomegalovirus therapy and the incidence of chronic graft-versus-host disease. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03871-4
Vancouver
Miyao K, Murata M, Nishida T, Ozawa Y, Uchida N, Fukuda T, et al. Association between early anti-cytomegalovirus therapy and the incidence of chronic graft-versus-host disease. International Journal of Hematology. 2025. doi:10.1007/s12185-024-03871-4
BibTeX
@article{Miyao2025,
author = {Miyao, Kotaro and Murata, Makoto and Nishida, Tetsuya and Ozawa, Yukiyasu and Uchida, Naoyuki and Fukuda, Takahiro and Doki, Noriko and Eto, Tetsuya and Kawakita, Toshiro and Mori, Yasuo and Takada, Satoru and Ohigashi, Hiroyuki and Tanaka, Masatsugu and Kanda, Yoshinobu and Matsuoka, Ken-Ichi and Ishimaru, Fumihiko and Atsuta, Yoshiko and Kanda, Junya and Terakura, Seitaro and GVHD Working Group of the Japanese Society for Transplantation and Cellular Therapy, GVHD Working Group of the Japanese Society for Transplantation and Cellular Therapy},
title = {Association between early anti-cytomegalovirus therapy and the incidence of chronic graft-versus-host disease},
journal = {International Journal of Hematology},
year = {2025},
doi = {10.1007/s12185-024-03871-4}
}
EUVIMED